HR 1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.

HR 1051 (Introduced in House)

Introduced in House text of HR 1051.

The document summary and details above are public. The full text is available to signed-in accounts.